5 evidence-based benefits of corticosteroid therapy for nasal polyps
Nasal polyps are noncancerous swellings of the sinonasal mucosa that commonly cause congestion, loss of smell, and reduced quality of life. Corticosteroids — delivered as intranasal sprays, short courses of oral tablets, or local steroid-eluting implants — are a foundational medical option for people with chronic rhinosinusitis with nasal polyps (CRSwNP). This article reviews five evidence-based benefits of corticosteroid therapy for nasal polyps, explains how and when different steroid approaches are used, and offers practical, safety-focused tips for patients and clinicians.
Background: why corticosteroids are used for nasal polyps
Nasal polyps form when chronic inflammation causes the nasal and sinus lining to thicken and protrude. In many cases this inflammation is driven by type 2 immune pathways, with eosinophil-predominant inflammation. Corticosteroids work by broadly suppressing inflammatory signaling, reducing tissue swelling, and lowering eosinophil activity. For decades, topical intranasal corticosteroids have been first-line therapy for patients with mild-to-moderate polyps, while short systemic steroid courses are used for more severe symptoms or rapid symptom control. New approaches such as steroid-eluting implants and biologic agents are emerging for refractory disease, but corticosteroids remain an evidence-based, widely used treatment option.
Key components of corticosteroid therapy for nasal polyps
Corticosteroid therapy for nasal polyps has three common delivery methods: (1) intranasal corticosteroid sprays or irrigations (daily, long-term), (2) short courses of oral systemic corticosteroids (prednisone, prednisolone — typically 7–14 days) for acute or severe flares, and (3) local, controlled-release steroid implants placed in the sinus cavities after surgery for targeted, prolonged delivery. Choice of route depends on polyp severity, prior treatments, comorbidities (for example asthma or aspirin-exacerbated respiratory disease), and patient preferences. Clinicians often combine approaches — for example a brief oral steroid course followed by regular intranasal spray — to achieve both rapid symptom relief and longer-term control.
Five evidence-based benefits of corticosteroid therapy for nasal polyps
1) Reduction in polyp size and nasal obstruction: Multiple randomized trials and controlled studies document that both systemic and topical corticosteroids reduce polyp bulk and improve nasal airflow. Short systemic courses produce rapid shrinkage; consistent intranasal therapy helps maintain reduced polyp size. For many patients the combined strategy (short oral course followed by intranasal maintenance) produces greater and more durable reduction in polyp grade than intranasal therapy alone.
2) Rapid improvement in symptoms, including nasal congestion: Oral corticosteroids can produce clinically meaningful symptom relief within days to a few weeks. Improvements commonly reported include reduced nasal blockage and decreased mucosal edema, which translate into better breathing and daily function.
3) Improved sense of smell (olfaction): Loss of smell is a frequent and distressing symptom of CRSwNP. Trials report significant recovery of olfactory function after short systemic steroid courses and after regular topical steroid use. Restoring odorant access to the olfactory cleft through decreased obstruction appears to be a key mechanism of smell improvement.
4) Reduction in local eosinophilic inflammation and markers of disease activity: Tissue studies show corticosteroids decrease eosinophilic infiltration and inflammatory mediators in polyp tissue. This anti-inflammatory effect helps explain improvements in symptoms, radiologic findings, and lower rates of acute exacerbation for some patients.
5) Delay or reduction in the need for surgery and improved postoperative outcomes: Preoperative systemic steroids can shrink polyps and improve surgical visualization, sometimes shortening operative time. Postoperative topical corticosteroids and implantable steroid devices may reduce early recurrence and reduce the need for repeat endoscopic sinus surgery in selected patients.
Benefits balanced with considerations and safety
While corticosteroids offer clear symptomatic and objective benefits, there are important limitations and safety considerations. The effect of a single short systemic course is often temporary — symptom and polyp recurrence is common over months if maintenance topical therapy is not used. Repeated or prolonged use of systemic corticosteroids raises risks including adrenal suppression, elevated blood glucose, hypertension, osteoporosis, mood changes, and immunosuppression. Therefore, guidelines generally recommend limiting systemic steroid courses and relying on intranasal maintenance therapy where possible. Local adverse effects of intranasal sprays are typically mild (epistaxis, nasal dryness). Steroid-eluting implants deliver high local doses with lower systemic exposure but are used in specific postoperative situations and require clinician placement.
Trends, innovations, and local clinical context
In the past decade, management of CRSwNP has shifted toward precision care: clinicians now integrate disease severity, biomarkers (such as blood eosinophils), comorbid asthma, and patient goals when selecting treatments. Biologic therapies targeting type 2 inflammation have expanded options for severe, recurrent polyposis, sometimes reducing reliance on systemic steroids. At the same time, improved topical delivery techniques (high-volume irrigations, steroid-impregnated rinses, and surgically placed steroid-eluting implants) aim to increase drug delivery to the sinuses while minimizing systemic effects. Local practice patterns vary: many clinicians in the United States still use a short systemic steroid course for rapid control, followed by long-term intranasal corticosteroid maintenance and consideration of surgery or biologics when indicated.
Practical tips for patients and clinicians
If you have nasal polyps and are considering corticosteroid therapy, discuss the following with your clinician: severity and duration of symptoms; prior response to intranasal steroids; comorbid conditions (asthma, diabetes, osteoporosis); and current medications. Typical pragmatic approaches include a short course of oral prednisone/prednisolone (commonly 7–14 days) for acute severe symptoms, followed by daily intranasal corticosteroid spray or high-volume steroid irrigation for maintenance. Use the prescribed intranasal technique (head position, nozzle direction) to improve delivery. Limit the number of systemic steroid courses per year when possible and consider alternative strategies (surgery, biologic therapy, steroid-eluting implants) for recurrent or steroid-dependent disease. Always monitor for systemic side effects after oral steroid use and screen patients at risk for complications (blood pressure, glucose control, bone health) when repeated systemic exposure is anticipated.
Summary of key points
Corticosteroids — especially when used thoughtfully as short systemic bursts followed by sustained intranasal maintenance — provide five measurable, evidence-based benefits for many people with nasal polyps: reduced polyp size, faster symptom relief, improved smell, decreased local eosinophilic inflammation, and potential to delay or improve surgical outcomes. Benefits must be balanced against the risks of systemic steroid exposure; personalized treatment plans, appropriate monitoring, and consideration of newer targeted therapies improve long-term outcomes. This information is educational and does not replace individualized medical advice. Speak with an otolaryngologist or your primary care provider about the best strategy for your situation.
Comparative overview: common corticosteroid approaches
| Delivery method | Typical use | Primary benefits | Main considerations |
|---|---|---|---|
| Intranasal corticosteroid spray (daily) | First-line maintenance therapy | Long-term symptom control; low systemic exposure | Requires consistent daily use; correct technique improves effectiveness |
| Short-course oral systemic corticosteroid (7–14 days) | Rapid control of severe symptoms or flares | Fast reduction in polyp size and congestion; improves smell | Systemic side effects; limit number of courses per year |
| Steroid-eluting sinus implant | Placed at time of sinus surgery for recurrent disease | High local dose with reduced systemic exposure; may reduce early recurrence | Used in specific postoperative settings; requires clinician placement |
Frequently asked questions
- Q: How long do steroid benefits last for nasal polyps? A: Short systemic courses typically produce rapid benefit that may wane over weeks to months unless followed by ongoing intranasal maintenance or other long-term treatments. Individual duration varies by disease severity and underlying inflammation.
- Q: Are nasal steroid sprays safe to use every day? A: For most patients, daily intranasal corticosteroid sprays are safe and well tolerated; local side effects like nasal dryness or nosebleed can occur. Long-term systemic effects are uncommon with topical use at standard doses.
- Q: How many times per year can I take oral steroids for polyps? A: Guidelines typically advise minimizing systemic steroid courses; many clinicians aim to limit short systemic courses to a small number per year (for example one to two) and seek alternative strategies for recurrent disease. Discuss individual risk vs. benefit with your clinician.
- Q: When should I consider surgery or biologic therapy instead of more steroids? A: Consider surgery if medical therapy (including topical steroids) fails to provide adequate control or if polyps obstruct the airway or sinuses. Biologic therapies may be appropriate for severe, recurrent CRSwNP, especially with type 2 inflammation and comorbid asthma — a specialist can help determine eligibility.
Sources
- Cochrane Review — Short-term oral corticosteroids as an addition to other treatments for chronic rhinosinusitis — evidence summary on systemic steroid courses and limitations.
- EPOS 2020 Executive Summary (European Position Paper on Rhinosinusitis and Nasal Polyps 2020) — guideline recommendations on use of topical and systemic corticosteroids.
- Randomized trial of short-course prednisolone for sinonasal polyposis (PubMed ID 16815148) — RCT supporting short systemic course benefits.
- Systematic review: efficacy and safety of intranasal corticosteroids in chronic rhinosinusitis (PubMed) — recent synthesis of topical steroid trials.
Medical disclaimer: This article is educational and does not replace individualized medical evaluation. If you have nasal polyps or worsening symptoms, consult an ear, nose and throat specialist (ENT) or your primary care clinician for personalized diagnosis and treatment.
This text was generated using a large language model, and select text has been reviewed and moderated for purposes such as readability.
